What would you what to see improved
with treatment in your child(ren) with
SSADHD?

Focus
Groups

• Special Education
• Impact on other
family members

• Improved speech
• Improved sleep
• Improved focus
• Improved social interactions
• Improved fine motor skills and decreased social anxiety
• Improved gross motor skills

• Safety information
What concerns would you have if you • History of the research on the therapeutic
were considering enrolling your child in a
• Invasiveness of the procedures
clinical trial for SSADHD treatment?
• Timetable and planning of the roll-out of the trial

What resources would your family need
if you were to enroll your child in a
clinical trial for SSADHD treatment?

• Risk v reward
• Contraindications with current medications
• Efficient communication that would allow for updates on the
clinical trial, results and future research

If there were a treatment available that
needed to be regularly administered to
your child with SSADHD, what would be
the best way to administer the
treatment?

• Preference for oral administration of treatment
• Injections would also be acceptable
• Considerations would have to be made regarding
interruptions for their school day

If you were responsible for administering • Overwhelming adamance that if there was a possibility that
this new treatment to your child with
their child’s and their family’s day-to-day experience would
SSADHD, up to how many times a day
improve, “nothing was off the table.”
would you be willing to administer
treatment?

Focus Group

• 3 of the participants were
individually representing
their child with SSADHD
• 1 participant was a
translator representing both
the mother and child with
SSADHD

• 2 participants were
representing their son with
SSADHD as the mother and
father
• 2 participants were
individually representing
their child with SSADHD as
their mother
• 1 participant was
individually representing
their child with SSADHD as
their father

In total, there were 17 participants of the focus groups, representing 15 individuals with SSADHD.

Focus Group Summary
• Communication • Sleep issues
What do you feel are the greatest
• Social interactions • Assistive Devices
impacts SSADHD has on your child’s day• Independence
to-day experience?

• 6 parents of individuals with
SSADHD
• 1 brother of 2 individuals
with SSADHD
• 1 great-grandmother of an
individual with SSADHD
• 2 of the parents were
representing their son with
SSADHD as the mother and
father
• 2 mothers and 1 father
were each individually
representing their child(ren)
with SSADHD

Focus Group

Succinic Semialdehyde Dehydrogenase Deficiency is a
rare, autosomal recessive disorder that is characterized by the
inefficient breakdown of GABA (gamma-Aminobutyric acid), an
inhibitory neurotransmitter. The lack of degradation leads to a
spectrum of neurological deficits, most commonly: seizures, ataxia,
hyporeflexia, and behavioral problems. There has been growing
interest in the impact of clinical trials on the quality of life of the
patients affected by SSADHD and their families. This study seeks to
understand highlighted concerns of caregivers and will serve as a
starting point to determine the focus of future of clinical trials.

Focus Group Participants
Focus Group

Introduction

❖ The project is an FDA-guided
qualitative needs assessment
from the caretaker community
of patients with SSADHD
❖ Serves as a first step in patientfocused therapeutic
development and evaluation for
SSADHD

Analysis
Patientcentered
Drug Trials

The objectives of these focus groups are the following:
❖ To identify endpoints/outcomes of interest to the SSADHD community
for clinical trials
❖ To determine the impact of clinical trial participation in the SSADHD
community

Conclusions
❖Clinical outcomes that assess communication ability,
cognitive functions, gross and fine motor skills.
❖Improvements in communications, independent
behavior, sleep and social interactions
❖A clinical research team that collaborates with families
and patients to coordinate trial procedures and clinical
care
❖Timing of clinical assessments planned accordingly to
needs and potential trial burden of patients
❖Materials about the nature of the study at the beginning
(including pre-clinical and preliminary clinical data), as
well as periodic updates to trial participants and their
families

Acknowledgements
Thank you to the families, care-givers, and patients who have taken the
time to participate in these focus groups. We also appreciate the work of
Dr. Mousumi Bose and her team at Montclair State University for leading
this project.

